Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors

    NEXT STORY
    AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
    PREV STORY
    Annual Financial Report
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Mesoblast Strengthens Key United States Patent Portfolio for the Treatment of Rheumatic Diseases

    NEW YORK and MELBOURNE, Australia, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) ...

    author_avatar
    NASDAQ Market News

    More people in Coimbatore living with kidney disease will have access to dialysis from today

    Fresenius Medical Care and Sri Ramakrishna Hospital inaugurate new dialysis center of excellence in ...

    author_avatar
    NASDAQ Market News

    BeiGene to Present at the William Blair 2018 Growth Stock Conference

    CAMBRIDGE, Mass. and BEIJING, China, June 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), ...

    author_avatar
    NASDAQ Market News